Rejuvenate Bio: Strategic

Funding history

Jun 8, 2026Strategic · This round$6M

Develops oligonucleotide therapeutics targeting chronic hepatitis B

$120MSeries C · Aug 27, 2026

Uses AI and proteomics to discover drug targets and biomarkers for preeclampsia and eclampsia

$35MStrategic · Aug 27, 2026

Physical AI platform capturing real-world lab science into machine-readable data

$25MSeed · Aug 26, 2026

Develops biologic therapies for respiratory and infectious diseases

$50MSeries E2 · Aug 25, 2026